1
|
Alexander MP, Zaidi M, Larson N, Mullan A, Pavelko KD, Stegall MD, Bentall A, Wouters BG, McKee T, Taner T. Exploring the single-cell immune landscape of kidney allograft inflammation using imaging mass cytometry. Am J Transplant 2024; 24:549-563. [PMID: 37979921 DOI: 10.1016/j.ajt.2023.11.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 11/01/2023] [Accepted: 11/11/2023] [Indexed: 11/20/2023]
Abstract
Kidney allograft inflammation, mostly attributed to rejection and infection, is an important cause of graft injury and loss. Standard histopathological assessment of allograft inflammation provides limited insights into biological processes and the immune landscape. Here, using imaging mass cytometry with a panel of 28 validated biomarkers, we explored the single-cell landscape of kidney allograft inflammation in 32 kidney transplant biopsies and 247 high-dimensional histopathology images of various phenotypes of allograft inflammation (antibody-mediated rejection, T cell-mediated rejection, BK nephropathy, and chronic pyelonephritis). Using novel analytical tools, for cell segmentation, we segmented over 900 000 cells and developed a tissue-based classifier using over 3000 manually annotated kidney microstructures (glomeruli, tubules, interstitium, and arteries). Using PhenoGraph, we identified 11 immune and 9 nonimmune clusters and found a high prevalence of memory T cell and macrophage-enriched immune populations across phenotypes. Additionally, we trained a machine learning classifier to identify spatial biomarkers that could discriminate between the different allograft inflammatory phenotypes. Further validation of imaging mass cytometry in larger cohorts and with more biomarkers will likely help interrogate kidney allograft inflammation in more depth than has been possible to date.
Collapse
Affiliation(s)
- Mariam P Alexander
- Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA.
| | - Mark Zaidi
- Department of Medical Biophysics, University of Toronto, Canada
| | - Nicholas Larson
- Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA
| | - Aidan Mullan
- Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA
| | - Kevin D Pavelko
- Immune Monitoring Core Laboratory, Mayo Clinic, Rochester, Minnesota, USA
| | - Mark D Stegall
- Departments of Surgery and Immunology, Mayo Clinic, Rochester, Minnesota, USA
| | - Andrew Bentall
- Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA
| | - Bradly G Wouters
- Department of Medical Biophysics, University of Toronto, Canada; Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Ontario, Canada
| | - Trevor McKee
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Pathomics Inc., Toronto, Ontario, Canada
| | - Timucin Taner
- Departments of Surgery and Immunology, Mayo Clinic, Rochester, Minnesota, USA
| |
Collapse
|
2
|
Ruzanov P, Evdokimova V, Pachva MC, Minkovich A, Zhang Z, Langman S, Gassmann H, Thiel U, Orlic-Milacic M, Zaidi SH, Peltekova V, Heisler LE, Sharma M, Cox ME, McKee TD, Zaidi M, Lapouble E, McPherson JD, Delattre O, Radvanyi L, Burdach SE, Stein LD, Sorensen PH. Oncogenic ETS fusions promote DNA damage and proinflammatory responses via pericentromeric RNAs in extracellular vesicles. J Clin Invest 2024; 134:e169470. [PMID: 38530366 PMCID: PMC11060741 DOI: 10.1172/jci169470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Accepted: 03/12/2024] [Indexed: 03/28/2024] Open
Abstract
Aberrant expression of the E26 transformation-specific (ETS) transcription factors characterizes numerous human malignancies. Many of these proteins, including EWS:FLI1 and EWS:ERG fusions in Ewing sarcoma (EwS) and TMPRSS2:ERG in prostate cancer (PCa), drive oncogenic programs via binding to GGAA repeats. We report here that both EWS:FLI1 and ERG bind and transcriptionally activate GGAA-rich pericentromeric heterochromatin. The respective pathogen-like HSAT2 and HSAT3 RNAs, together with LINE, SINE, ERV, and other repeat transcripts, are expressed in EwS and PCa tumors, secreted in extracellular vesicles (EVs), and are highly elevated in plasma of patients with EwS with metastatic disease. High human satellite 2 and 3 (HSAT2,3) levels in EWS:FLI1- or ERG-expressing cells and tumors were associated with induction of G2/M checkpoint, mitotic spindle, and DNA damage programs. These programs were also activated in EwS EV-treated fibroblasts, coincident with accumulation of HSAT2,3 RNAs, proinflammatory responses, mitotic defects, and senescence. Mechanistically, HSAT2,3-enriched cancer EVs induced cGAS-TBK1 innate immune signaling and formation of cytosolic granules positive for double-strand RNAs, RNA-DNA, and cGAS. Hence, aberrantly expressed ETS proteins derepress pericentromeric heterochromatin, yielding pathogenic RNAs that transmit genotoxic stress and inflammation to local and distant sites. Monitoring HSAT2,3 plasma levels and preventing their dissemination may thus improve therapeutic strategies and blood-based diagnostics.
Collapse
Affiliation(s)
- Peter Ruzanov
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | | | - Manideep C. Pachva
- Department of Molecular Oncology, British Columbia Cancer Research Centre and
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Alon Minkovich
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - Zhenbo Zhang
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - Sofya Langman
- Department of Molecular Oncology, British Columbia Cancer Research Centre and
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Hendrik Gassmann
- Department of Pediatrics, Children’s Cancer Research Center, Kinderklinik München Schwabing, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany
| | - Uwe Thiel
- Department of Pediatrics, Children’s Cancer Research Center, Kinderklinik München Schwabing, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany
| | | | - Syed H. Zaidi
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - Vanya Peltekova
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | | | - Manju Sharma
- Vancouver Prostate Centre, Vancouver, British Columbia, Canada
| | - Michael E. Cox
- Vancouver Prostate Centre, Vancouver, British Columbia, Canada
| | - Trevor D. McKee
- STTARR Innovation Centre, Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
- Pathomics Inc., Toronto, Ontario, Canada
| | - Mark Zaidi
- Pathomics Inc., Toronto, Ontario, Canada
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
| | - Eve Lapouble
- Unité Génétique Somatique (UGS), Institut Curie, Centre Hospitalier Paris, France
| | - John D. McPherson
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
- Department of Biochemistry and Molecular Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, California, USA
| | - Olivier Delattre
- Unité Génétique Somatique (UGS), Institut Curie, Centre Hospitalier Paris, France
- Diversity and Plasticity of Childhood tumors, INSERM U830, Institut Curie Research Center, PSL Research University, Paris, France
| | - Laszlo Radvanyi
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
- Department of Immunology, University of Toronto, Toronto, Ontario, Canada
| | - Stefan E.G. Burdach
- Department of Molecular Oncology, British Columbia Cancer Research Centre and
- Department of Pediatrics, Children’s Cancer Research Center, Kinderklinik München Schwabing, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany
- CCC München Comprehensive Cancer Center, DKTK German Cancer Consortium, Munich, Germany
- Institute of Pathology, Translation Pediatric Cancer Research Action, School of Medicine, Technical University of Munich, Munich, Germany
| | - Lincoln D. Stein
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
- Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
| | - Poul H. Sorensen
- Department of Molecular Oncology, British Columbia Cancer Research Centre and
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
3
|
Farooqui N, Zaidi M, Vaughan L, McKee TD, Ahsan E, Pavelko KD, Villasboas JC, Markovic S, Taner T, Leung N, Dong H, Alexander MP, Herrmann SM. Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors. Kidney Int Rep 2023; 8:628-641. [PMID: 36938084 PMCID: PMC10014345 DOI: 10.1016/j.ekir.2022.11.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Revised: 10/25/2022] [Accepted: 11/28/2022] [Indexed: 12/12/2022] Open
Abstract
Introduction Immune checkpoint inhibitors (ICIs) induce impressive antitumor responses but may lead to acute kidney injury (AKI) associated with ICI therapy (AKI-ICI). Biomarkers distinguishing AKI-ICI from AKI because of other causes (AKI-other) are currently lacking. Because ICIs block immunoregulatory pathways, we hypothesized that biomarkers related to immune cell dysregulation, including tumor necrosis factor alpha (TNF-α) and other markers of B and T cell activation in the systemic circulation and kidney tissue, may aid with the diagnosis of AKI-ICI. Methods This is a prospective study consisting of 24 participants who presented with AKI during ICI therapy, adjudicated to either have AKI-ICI (n = 14) or AKI-other (n = 10). We compared markers of kidney inflammation and injury (neutrophil gelatinase-associated lipocalin, kidney injury molecule-1) as well as plasma and urine levels of T cell-associated cytokines (TNF-α, interferon-γ, interleukin (IL)-2, IL-4, IL-6, IL-8, IL-9, and IL-10) between groups. We also compared T-cell responses in the systemic circulation and in kidney tissue across groups, using mass cytometry systems. Results We observed increase in several specific immune cells, including CD4 memory, T helper cells, and dendritic cells in the kidney tissue, as well as in the urine cytokines IL-2, IL-10, and TNF-α, in patients who developed AKI-ICI compared to patients with AKI-other (P < 0.05 for all). The discriminatory ability of TNF-α on AKI cause was strong (area under the curve = 0.814, 95% confidence interval: 0.623-1.00. The CD4+ T cells with memory phenotype formed the dominant subset. Conclusion These results suggest that specific T-cell responses and their respective cytokines may be indicative of AKI associated with ICI therapy and may help to differentiate AKI-ICI from AKI-other. Urine TNF-α is a promising biomarker for AKI-ICI, which is most often caused by acute interstitial nephritis (AIN), and TNF-α pathway may serve as a potential target for therapeutic intervention.
Collapse
Affiliation(s)
- Naba Farooqui
- Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA
| | - Mark Zaidi
- Department of Medical Biophysics, University of Toronto, Ontario, Canada
| | - Lisa Vaughan
- Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA
| | - Trevor D. McKee
- Department of Medical Biophysics, University of Toronto, Ontario, Canada
- Deciphex Inc., Chicago, Illinois, USA
| | - Eram Ahsan
- Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA
| | - Kevin D. Pavelko
- Department of Immunology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA
| | | | | | - Timucin Taner
- Department of Immunology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA
- Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA
| | - Nelson Leung
- Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA
| | - Haidong Dong
- Department of Immunology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA
| | - Mariam P. Alexander
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
| | - Sandra M. Herrmann
- Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA
| |
Collapse
|
4
|
Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Grénman RA, Caporiccio L, McKee TD, Zaidi M, Butt S, Macann AM, McIvor NP, Chaplin JM, Hicks KO, Bohlander SK, Wouters BG, Hart CP, Print CG, Wilson WR, Curran MA, Hunter FW. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. JCI Insight 2023; 8:169136. [PMID: 36810255 PMCID: PMC9990753 DOI: 10.1172/jci.insight.169136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023] Open
|
5
|
Katz L, Woolman M, Kiyota T, Pires L, Zaidi M, Hofer SO, Leong W, Wouters BG, Ghazarian D, Chan AW, Ginsberg HJ, Aman A, Wilson BC, Berman HK, Zarrine-Afsar A. Picosecond Infrared Laser Mass Spectrometry Identifies a Metabolite Array for 10 s Diagnosis of Select Skin Cancer Types: A Proof-of-Concept Feasibility Study. Anal Chem 2022; 94:16821-16830. [DOI: 10.1021/acs.analchem.2c03918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Affiliation(s)
- Lauren Katz
- Techna Institute for the Advancement of Technology for Health, University Health Network, 100 College Street, Toronto, Ontario M5G 1P5, Canada
- Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada
| | - Michael Woolman
- Techna Institute for the Advancement of Technology for Health, University Health Network, 100 College Street, Toronto, Ontario M5G 1P5, Canada
- Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada
| | - Taira Kiyota
- Ontario Institute for Cancer Research (OICR), 661 University Ave Suite 510, Toronto, Ontario M5G 0A3, Canada
| | - Layla Pires
- Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada
- Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, Ontario M5G 2C1, Canada
| | - Mark Zaidi
- Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada
| | - Stefan O.P. Hofer
- Techna Institute for the Advancement of Technology for Health, University Health Network, 100 College Street, Toronto, Ontario M5G 1P5, Canada
- Department of Surgery, University of Toronto, 149 College Street, Toronto, Ontario M5T 1P5, Canada
- Division of Plastic and Reconstructive Surgery, Department of Surgery and Surgical Oncology, University Health Network, University of Toronto. Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada
| | - Wey Leong
- Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, Ontario M5G 2C1, Canada
- Department of Surgery, University of Toronto, 149 College Street, Toronto, Ontario M5T 1P5, Canada
- Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto Ontario M5G 2C1, Canada
| | - Brad G. Wouters
- Techna Institute for the Advancement of Technology for Health, University Health Network, 100 College Street, Toronto, Ontario M5G 1P5, Canada
- Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada
- Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, Ontario M5G 2C1, Canada
| | - Danny Ghazarian
- Department of Laboratory Medicine and Pathobiology, University of Toronto and University Health Network, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada
| | - An-Wen Chan
- Division of Dermatology, Department of Medicine, University of Toronto, Canada and Women’s College Research Institute, Women’s College Hospital, 76 Grenville St, Toronto, Ontario M5S 1B2, Canada
| | - Howard J. Ginsberg
- Techna Institute for the Advancement of Technology for Health, University Health Network, 100 College Street, Toronto, Ontario M5G 1P5, Canada
- Department of Surgery, University of Toronto, 149 College Street, Toronto, Ontario M5T 1P5, Canada
- Keenan Research Center for Biomedical Science & the Li Ka Shing Knowledge Institute, St. Michael’s Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada
| | - Ahmed Aman
- Ontario Institute for Cancer Research (OICR), 661 University Ave Suite 510, Toronto, Ontario M5G 0A3, Canada
- Leslie Dan, Faculty of Pharmacy, University of Toronto, 144 College St, Toronto, Ontario M5S 3M2, Canada
| | - Brian C. Wilson
- Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada
- Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, Ontario M5G 2C1, Canada
| | - Hal K. Berman
- Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, Ontario M5G 2C1, Canada
- Laboratory Medicine Program, University Health Network, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada
| | - Arash Zarrine-Afsar
- Techna Institute for the Advancement of Technology for Health, University Health Network, 100 College Street, Toronto, Ontario M5G 1P5, Canada
- Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada
- Department of Surgery, University of Toronto, 149 College Street, Toronto, Ontario M5T 1P5, Canada
- Keenan Research Center for Biomedical Science & the Li Ka Shing Knowledge Institute, St. Michael’s Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada
| |
Collapse
|
6
|
Mansouri S, Zaidi M, Singh O, Ali H, Karimi S, Lombard P, Dvorkin-Gheva A, Velasquez C, Devaraja K, Sosa J, Patil V, Wei Q, Wu R, Li M, Cheung M, Voisin M, Gao A, Hedley D, Aldape K, Wouters B, Zadeh G. TMIC-73. HIGH-DIMENSIONAL HISTOPATHOLOGIC EVALUATION OF THE HYPOXIC MICROENVIRONMENT IN GLIOBLASTOMA. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac209.1116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
Rapidly growing solid tumors such as glioblastoma (GBM) are characteristically hypoxic, displaying large areas of necrosis surrounded by hyperproliferative pseudopalisading cells. Intra-tumoral hypoxia develops over time in the three-dimensional space and the degree of tissue oxygenation is a dynamic process that varies continuously. Combined with the extensive inter- and intra-tumoral heterogeneity associated with GBM at the bulk and single cell level, hypoxia contributes to a gradient of molecular alterations that are specific to the different cell populations that make up the bulk of the tumor and reside in specific niches. To date, high dimensional histopathologic analyses of the hypoxic regions within GBM tissue have not been performed. Here, we took a combined spatial and single-cell proteomic profiling approach to investigate the histopathologic features of hypoxia by leveraging a unique clinical study where the exogenous hypoxia marker pimonidazole (PIMO) is administered to patients with GBM prior to surgery. Tissue specimens were subjected to imaging mass cytometry and serial immunohistochemistry using a panel of 27 markers associated with cellular hallmarks of hypoxia, metabolism, proliferation, stemness, angiogenesis, and immune cell types. We took high-resolution imaging and statistical approaches to explore the interplay of the different markers within hypoxic regions of primary and recurrent GBMs, in addition to IDH-mutant gliomas. Our findings elucidate the expression pattern of key biological markers relative to one another, altered composition of different cell types, along with differential proliferative, transcriptional, and translational activation states associated with each cell type within the hypoxic regions of GBM.
Collapse
Affiliation(s)
| | | | - Olivia Singh
- MacFeeters Hamilton Centre for Neuro-Oncology Research, Toronto , Ontario , Canada
| | | | | | | | | | | | | | | | - Vikas Patil
- MacFeeters-Hamilton Center for Neuro-Oncology Research, Princess Margaret Cancer Centre , Toronto , Canada
| | - Qingxia Wei
- MacFeeters Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Centre , Toronto , Canada
| | | | | | | | | | | | | | - Kenneth Aldape
- Laboratory of Pathology, National Cancer Institute, National Institutes of Health , Bethesda , USA
| | | | - Gelareh Zadeh
- Princess Margaret Cancer Center and MacFeeters-Hamilton Center for Neuro-Oncology Research, University Health Network, Wilkins Family Chair in Brain Tumor Research , Toronto , Canada
| |
Collapse
|
7
|
Lombard P, Zaidi M, Mansouri S, Zadeh G, Wouters B. Spatial transcriptomics analysis for spatial biomarker discovery in glioblastoma. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01123-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
8
|
Botté A, Seguin C, Nahrgang J, Zaidi M, Guery J, Leignel V. Lead in the marine environment: concentrations and effects on invertebrates. Ecotoxicology 2022; 31:194-207. [PMID: 35037181 DOI: 10.1007/s10646-021-02504-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 11/16/2021] [Indexed: 06/14/2023]
Abstract
Lead (Pb) is a non-essential metal naturally present in the environment and often complexed with other elements (e.g., copper, selenium, zinc). This metal has been used since ancient Egypt and its extraction has grown in the last centuries. It has been used until recently as a fuel additive and is currently used in the production of vehicle batteries, paint, and plumbing. Marine ecosystems are sinks of terrestrial contaminations; consequently, lead is detected in oceans and seas. Furthermore, lead is not biodegradable. It remains in soil, atmosphere, and water inducing multiple negative impacts on marine invertebrates (key species in trophic chain) disturbing ecological ecosystems. This review established our knowledge on lead accumulation and its effects on marine invertebrates (Annelida, Cnidaria, Crustacea, Echinodermata, and Mollusca). Lead may affect different stages of development from fertilization to larval development and can also lead to disturbance in reproduction and mortality. Furthermore, we discussed changes in the seawater chemistry due to Ocean Acidification, which can affect the solubility, speciation, and distribution of the lead, increasing potentially its toxicity to marine invertebrates.
Collapse
Affiliation(s)
- A Botté
- Laboratoire Biologie des organismes, Stress, Santé, Environnement (BIOSSE), Le Mans Université, Le Mans, France
| | - C Seguin
- Laboratoire Biologie des organismes, Stress, Santé, Environnement (BIOSSE), Le Mans Université, Le Mans, France
| | - J Nahrgang
- UiT, University Arctic of Norway, Department of Marine Biology, Tromsø, Norway
| | - M Zaidi
- Laboratoire Biologie des organismes, Stress, Santé, Environnement (BIOSSE), Le Mans Université, Le Mans, France
| | - J Guery
- Institut des Molécules et Matériaux du Mans (IMMM), UMR CNRS 5283, Le Mans Université, Le Mans, France
| | - V Leignel
- Laboratoire Biologie des organismes, Stress, Santé, Environnement (BIOSSE), Le Mans Université, Le Mans, France.
| |
Collapse
|
9
|
Zaidi M, Lombard P, Mansouri S, Zadeh G, McKee TD, Wouters BG. Abstract LBA029: Development of computational tools for evaluating differential protein expression relative to spatial oxygen gradients using imaging mass cytometry. Mol Cancer Ther 2021. [DOI: 10.1158/1535-7163.targ-21-lba029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The solid tumor microenvironment is highly heterogeneous, conferring numerous differences in tumor cell gene expression and phenotype. One predominant driver of this heterogeneity is variable oxygenation. Low oxygen, termed hypoxia, has been shown to increase metastasis, radiation resistance, and lead to an overall poor patient prognosis. Characterizing hypoxia in patients can be used to personalize an adjuvant therapy targeting resistant hypoxic cell populations, which may otherwise survive conventional therapies. Because of the spatial heterogeneity intrinsic to hypoxia, current approaches to measure hypoxia, such as using polarographic oxygen electrodes, may underestimate the severity of hypoxia. Endogenous markers such as CA9 and VEGFA provide some semblance of evaluating hypoxia, however expression of such markers is not always solely driven by oxygenation. Multiple markers in tandem may prove to be a more reliable metric for evaluating hypoxia than individual markers alone. Here, we present an open-source collection of QuPath and Python scripts for analyzing differential protein expression relative to hypoxia gradients for imaging mass cytometry (IMC) data. IMC enables highly multiplexed imaging of tissue sections at the single cell resolution, with no spectral overlap of immunohistochemical markers. This is achieved through substitution of fluorophores with unique isotopes of heavy metals, and a mass spectrometer in place of a conventional fluorescent microscope. Previous work in our lab has identified 17 markers with extensive heterogeneity in clinical glioblastoma multiforme (GBM) patient samples. Pimonidazole, an exogenous hypoxia probe, has been administered to these patients, and is detectable through immunohistochemical techniques such as IMC. Serving as our ground truth for hypoxia, we conduct a differential gene expression analysis across regions of relative hypoxia for all markers in our panel, using a variety of supervised and unsupervised tools available in the open-source digital pathology platform QuPath, and through custom data visualization and statistical analysis tools built in Python. As such, we present an end-to-end image analysis workflow for evaluating hypoxia-regulated differential protein expression of clinical GBM cases imaged through IMC. This method is applicable for evaluating differential gene expression across multiple disease sites, multiplexed imaging modalities, and histomorphological regions of interest. Such computational methods enable high throughput biomarker discovery, while also being used to elucidate novel oxygen-dependent biological pathways.
Citation Format: Mark Zaidi, Phoebe Lombard, Sheila Mansouri, Gelareh Zadeh, Trevor D McKee, Bradly G Wouters. Development of computational tools for evaluating differential protein expression relative to spatial oxygen gradients using imaging mass cytometry [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2021 Oct 7-10. Philadelphia (PA): AACR; Mol Cancer Ther 2021;20(12 Suppl):Abstract nr LBA029.
Collapse
Affiliation(s)
- Mark Zaidi
- 1University of Toronto, Toronto, ON, Canada,
| | | | | | | | | | | |
Collapse
|
10
|
Zaidi M, Tatterton M, May-Miller P, Agrawal A. Ultrasound-positive axillary lymph nodes in early breast cancer: can a patient subgroup avoid axillary lymph node dissection? A simple algorithm is suggested. Ann R Coll Surg Engl 2021; 104:48-52. [PMID: 34730418 DOI: 10.1308/rcsann.2020.7122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
INTRODUCTION National UK guidelines suggest that axillary lymph node dissection (ALND) is no longer mandatory for selected early node-positive breast cancer patients. Our study aimed to identify patients with early breast cancer and ultrasound (USS)-positive axillary metastasis who possess low burden of axillary disease and can avoid ALND. METHODS We conducted a 5-year study of prospectively collected data of patients with clinically T1-2, N0 breast cancer and a positive USS-guided axillary biopsy. Primary outcome was involvement of 1-2 lymph nodes (low disease burden) or ≥3 lymph nodes (higher axillary disease) on final ALND histology. Tumour type, size, grade, multifocality, receptor status, number of abnormal imaged nodes and presence of lympho-vascular invasion (LVI) were recorded. Data were analysed using chi-squared and Student's t-test. RESULTS One hundred and sixty-six patients underwent ALND for pT1-2 breast cancer. Seventy patients had no clinically palpable lymphadenopathy but a positive USS-guided biopsy. Of 70 patients, 32 women (46%) had low disease burden, whereas 38 women (54%) had higher axillary disease in final histology. LVI and >1 abnormal lymph node on USS were both significantly associated with higher disease burden (p = 0.050 and 0.009, respectively). CONCLUSION Our study confirms the presence of an important patient cohort, who are clinically node-negative with a positive USS-guided biopsy and a low volume of axillary disease. No imaging modality currently has the accuracy required to identify patients with this low disease burden preoperatively but we propose a simple algorithm for axillary management in this subgroup.
Collapse
Affiliation(s)
- M Zaidi
- Queen Alexandra Hospital, UK
| | | | | | | |
Collapse
|
11
|
Alder L, Zaidi M, Zeidan B, Mazari F. Advanced breast conservation and partial breast reconstruction - a review of current available options for oncoplastic breast surgery. Ann R Coll Surg Engl 2021; 104:319-323. [PMID: 34415191 DOI: 10.1308/rcsann.2021.0169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Breast cancer is the most common cancer affecting one in three women with new cancer diagnosis in England. Breast-conserving surgery is the primary surgical option in a vast majority of these patients. Use of oncoplastic techniques in breast conservation surgery has significantly improved the aesthetic outcomes without compromising the oncological safety of cancer resections. Oncoplastic breast-conserving surgery (OPBCS) has transformed the specialty with a paradigm shift in ideology and the recognition that aesthetic and oncological resections are synonymous when planning surgical intervention for patients with breast cancer. The two main options for OPBCS are therapeutic mammoplasty and partial beast reconstruction using pedicle-based flaps. This review aims to highlight key concepts in OPBCS demonstrating an overview of these surgical techniques, their safety, outcomes and the emergence of extreme oncoplastic breast surgery.
Collapse
Affiliation(s)
- L Alder
- University Hospital Southampton NHS Foundation Trust, UK
| | - M Zaidi
- Portsmouth Hospitals NHS Trust, UK
| | - B Zeidan
- University Hospital Southampton NHS Foundation Trust, UK
| | - Fak Mazari
- University Hospital Southampton NHS Foundation Trust, UK
| |
Collapse
|
12
|
Woolman M, Katz L, Gopinath G, Kiyota T, Kuzan-Fischer CM, Ferry I, Zaidi M, Peters K, Aman A, McKee T, Fu F, Amara-Belgadi S, Daniels C, Wouters BG, Rutka JT, Ginsberg HJ, McIntosh C, Zarrine-Afsar A. Mass Spectrometry Imaging Reveals a Gradient of Cancer-like Metabolic States in the Vicinity of Cancer Not Seen in Morphometric Margins from Microscopy. Anal Chem 2021; 93:4408-4416. [PMID: 33651938 DOI: 10.1021/acs.analchem.0c04129] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Spatially resolved ambient mass spectrometry imaging methods have gained popularity to characterize cancer sites and their borders using molecular changes in the lipidome. This utility, however, is predicated on metabolic homogeneity at the border, which would create a sharp molecular transition at the morphometric borders. We subjected murine models of human medulloblastoma brain cancer to mass spectrometry imaging, a technique that provides a direct readout of tissue molecular content in a spatially resolved manner. We discovered a distance-dependent gradient of cancer-like lipid molecule profiles in the brain tissue within 1.2 mm of the cancer border, suggesting that a cancer-like state progresses beyond the histologic border, into the healthy tissue. The results were further corroborated using orthogonal liquid chromatography and mass spectrometry (LC-MS) analysis of selected tissue regions subjected to laser capture microdissection. LC-MS/MS analysis for robust identification of the affected molecules implied changes in a number of different lipid classes, some of which are metabolized from the essential docosahexaenoic fatty acid (DHA) present in the interstitial fluid. Metabolic molecular borders are thus not as sharp as morphometric borders, and mass spectrometry imaging can reveal molecular nuances not observed with microscopy. Caution must be exercised in interpreting multimodal imaging results stipulated on a coincidental relationship between metabolic and morphometric borders of cancer, at least within animal models used in preclinical research.
Collapse
Affiliation(s)
- Michael Woolman
- Techna Institute for the Advancement of Technology for Health, University Health Network, 100 College Street, Toronto, Ontario M5G 1P5, Canada.,Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada
| | - Lauren Katz
- Techna Institute for the Advancement of Technology for Health, University Health Network, 100 College Street, Toronto, Ontario M5G 1P5, Canada.,Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada
| | - Georgia Gopinath
- Techna Institute for the Advancement of Technology for Health, University Health Network, 100 College Street, Toronto, Ontario M5G 1P5, Canada.,Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada
| | - Taira Kiyota
- Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, Toronto, Ontario M5G 0A3, Canada
| | - Claudia M Kuzan-Fischer
- Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada.,Developmental & Stem Cell Biology Program, The Hospital for Sick Children, 686 Bay Street, Toronto, Ontario M5G 0A4, Canada
| | - Isabelle Ferry
- Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada.,Developmental & Stem Cell Biology Program, The Hospital for Sick Children, 686 Bay Street, Toronto, Ontario M5G 0A4, Canada
| | - Mark Zaidi
- Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada.,STTARR Innovation Centre, 101 College Street, Toronto, Ontario M5G 1L7, Canada
| | - Kaitlyn Peters
- Techna Institute for the Advancement of Technology for Health, University Health Network, 100 College Street, Toronto, Ontario M5G 1P5, Canada.,Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada
| | - Ahmed Aman
- Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, Toronto, Ontario M5G 0A3, Canada.,Leslie Dan Faculty of Pharmacy, 144 College Street, Toronto, Ontario M5S 3M2, Canada
| | - Trevor McKee
- Techna Institute for the Advancement of Technology for Health, University Health Network, 100 College Street, Toronto, Ontario M5G 1P5, Canada.,STTARR Innovation Centre, 101 College Street, Toronto, Ontario M5G 1L7, Canada
| | - Fred Fu
- STTARR Innovation Centre, 101 College Street, Toronto, Ontario M5G 1L7, Canada
| | - Siham Amara-Belgadi
- Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada
| | - Craig Daniels
- Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada.,Developmental & Stem Cell Biology Program, The Hospital for Sick Children, 686 Bay Street, Toronto, Ontario M5G 0A4, Canada
| | - Brad G Wouters
- Techna Institute for the Advancement of Technology for Health, University Health Network, 100 College Street, Toronto, Ontario M5G 1P5, Canada.,Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada
| | - James T Rutka
- Department of Surgery, University of Toronto, 149 College Street, Toronto, Ontario M5T 1P5, Canada.,Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada
| | - Howard J Ginsberg
- Techna Institute for the Advancement of Technology for Health, University Health Network, 100 College Street, Toronto, Ontario M5G 1P5, Canada.,Department of Surgery, University of Toronto, 149 College Street, Toronto, Ontario M5T 1P5, Canada.,Keenan Research Center for Biomedical Science & The Li Ka Shing Knowledge Institute, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada.,Institute of Biomaterials and Biomedical Engineering, University of Toronto, 164 College Street, Toronto, Ontario M5S 3G9, Canada
| | - Chris McIntosh
- Techna Institute for the Advancement of Technology for Health, University Health Network, 100 College Street, Toronto, Ontario M5G 1P5, Canada.,Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada.,Peter Munk Cardiac Centre, Joint Department of Medical Imaging, University Health Network, Toronto, Ontario M5G 2N2, Canada.,Vector Institute for Artificial Intelligence, Toronto, Ontario M5G 1M1, Canada
| | - Arash Zarrine-Afsar
- Techna Institute for the Advancement of Technology for Health, University Health Network, 100 College Street, Toronto, Ontario M5G 1P5, Canada.,Department of Medical Biophysics, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada.,Department of Surgery, University of Toronto, 149 College Street, Toronto, Ontario M5T 1P5, Canada.,Keenan Research Center for Biomedical Science & The Li Ka Shing Knowledge Institute, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada
| |
Collapse
|
13
|
Zaidi M, Cui H, Wang B, McKee TD, Wouters BG. Abstract PO-018: Computational staining of tumor hypoxia from H&E images using convolutional neural networks. Clin Cancer Res 2021. [DOI: 10.1158/1557-3265.adi21-po-018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Heterogeneity in the tumor environment can be driven by multiple biochemical processes, such as immune infiltration, cell-to-cell genetic variation, and oxygenation gradients. Low oxygen, termed hypoxia, has been strongly correlated with metastasis, radiation resistance, and poor prognosis. One ongoing challenge is determining the magnitude of how hypoxia influences treatment response relative to other features, such as proliferation and micro vessel density. While it is possible to stain banked tissue for these markers, it is challenging to stain for endogenous markers of hypoxia. Exogenous probes have been developed to overcome this barrier; however, most clinical samples lack such probes. Previously, we have shown that spatial distributions of hypoxia correlate with morphological features of the tumor, such as necrosis and vasculature. Some of these features can be identified in hematoxylin and eosin (H&E)-stained sections, present for nearly all tumor samples. We hypothesize that a trained machine learning algorithm can be used to accurately predict hypoxia distributions given an H&E-stained section. Colorectal, pancreatic, and ovarian cancer cell line xenografts were cut and stained for markers of hypoxia, proliferation, perfusion, vasculature, and H&E. Binary masks of necrosis were generated, and together with the H&E and hypoxia images, were used to train a convolutional neural network. Once the model had been trained, a fairly precise prediction (MSE <0.012) had been obtained relative to the ground-truth hypoxia stained images. We believe a model trained on clinical H&E and hypoxia sections can be used to accurately predict hypoxia distributions from a H&E section. Predicted hypoxia distributions from existing H&E histology can be used to evaluate the influence of hypoxia on treatment outcome, by retroactively comparing a patient’s prognosis with levels of hypoxia. Correlations between hypoxia and prognostic measures such as tumor volume after irradiation, would indicate hypoxia may have modulated the efficacy of the treatment. Thus, computational stain prediction of hypoxia can serve as an invaluable tool in closing the gap between preclinical and clinical implementations of hypoxia-targeted therapies.
Citation Format: Mark Zaidi, Haotian Cui, Bo Wang, Trevor D. McKee, Bradly G. Wouters. Computational staining of tumor hypoxia from H&E images using convolutional neural networks [abstract]. In: Proceedings of the AACR Virtual Special Conference on Artificial Intelligence, Diagnosis, and Imaging; 2021 Jan 13-14. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(5_Suppl):Abstract nr PO-018.
Collapse
Affiliation(s)
- Mark Zaidi
- 1University of Toronto, Toronto, ON, Canada,
| | - Haotian Cui
- 1University of Toronto, Toronto, ON, Canada,
| | - Bo Wang
- 1University of Toronto, Toronto, ON, Canada,
| | | | | |
Collapse
|
14
|
Woolman M, Qiu J, Kuzan-Fischer CM, Ferry I, Dara D, Katz L, Daud F, Wu M, Ventura M, Bernards N, Chan H, Fricke I, Zaidi M, Wouters BG, Rutka JT, Das S, Irish J, Weersink R, Ginsberg HJ, Jaffray DA, Zarrine-Afsar A. In situ tissue pathology from spatially encoded mass spectrometry classifiers visualized in real time through augmented reality. Chem Sci 2020; 11:8723-8735. [PMID: 34123126 PMCID: PMC8163395 DOI: 10.1039/d0sc02241a] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Integration between a hand-held mass spectrometry desorption probe based on picosecond infrared laser technology (PIRL-MS) and an optical surgical tracking system demonstrates in situ tissue pathology from point-sampled mass spectrometry data. Spatially encoded pathology classifications are displayed at the site of laser sampling as color-coded pixels in an augmented reality video feed of the surgical field of view. This is enabled by two-way communication between surgical navigation and mass spectrometry data analysis platforms through a custom-built interface. Performance of the system was evaluated using murine models of human cancers sampled in situ in the presence of body fluids with a technical pixel error of 1.0 ± 0.2 mm, suggesting a 84% or 92% (excluding one outlier) cancer type classification rate across different molecular models that distinguish cell-lines of each class of breast, brain, head and neck murine models. Further, through end-point immunohistochemical staining for DNA damage, cell death and neuronal viability, spatially encoded PIRL-MS sampling is shown to produce classifiable mass spectral data from living murine brain tissue, with levels of neuronal damage that are comparable to those induced by a surgical scalpel. This highlights the potential of spatially encoded PIRL-MS analysis for in vivo use during neurosurgical applications of cancer type determination or point-sampling in vivo tissue during tumor bed examination to assess cancer removal. The interface developed herein for the analysis and the display of spatially encoded PIRL-MS data can be adapted to other hand-held mass spectrometry analysis probes currently available. Integration between a hand-held mass spectrometry desorption probe based on picosecond infrared laser technology (PIRL-MS) and an optical surgical tracking system demonstrates in situ tissue pathology from point-sampled mass spectrometry data.![]()
Collapse
Affiliation(s)
- Michael Woolman
- Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada +1-416-581-8473.,Department of Medical Biophysics, University of Toronto 101 College Street Toronto ON M5G 1L7 Canada
| | - Jimmy Qiu
- Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada +1-416-581-8473
| | - Claudia M Kuzan-Fischer
- Peter Gilgan Centre for Research and Learning, Hospital for Sick Children 686 Bay Street Toronto ON M5G 0A4 Canada.,Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children Toronto ON M5G 1X8 Canada
| | - Isabelle Ferry
- Peter Gilgan Centre for Research and Learning, Hospital for Sick Children 686 Bay Street Toronto ON M5G 0A4 Canada.,Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children Toronto ON M5G 1X8 Canada
| | - Delaram Dara
- Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada +1-416-581-8473
| | - Lauren Katz
- Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada +1-416-581-8473.,Department of Medical Biophysics, University of Toronto 101 College Street Toronto ON M5G 1L7 Canada
| | - Fowad Daud
- Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada +1-416-581-8473.,Department of Medical Biophysics, University of Toronto 101 College Street Toronto ON M5G 1L7 Canada
| | - Megan Wu
- Peter Gilgan Centre for Research and Learning, Hospital for Sick Children 686 Bay Street Toronto ON M5G 0A4 Canada
| | - Manuela Ventura
- Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada +1-416-581-8473
| | - Nicholas Bernards
- Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada +1-416-581-8473
| | - Harley Chan
- Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada +1-416-581-8473
| | - Inga Fricke
- Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada +1-416-581-8473
| | - Mark Zaidi
- Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada +1-416-581-8473
| | - Brad G Wouters
- Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada +1-416-581-8473.,Department of Medical Biophysics, University of Toronto 101 College Street Toronto ON M5G 1L7 Canada
| | - James T Rutka
- Peter Gilgan Centre for Research and Learning, Hospital for Sick Children 686 Bay Street Toronto ON M5G 0A4 Canada.,Department of Surgery, University of Toronto 149 College Street Toronto ON M5T 1P5 Canada.,Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children Toronto ON M5G 1X8 Canada
| | - Sunit Das
- Peter Gilgan Centre for Research and Learning, Hospital for Sick Children 686 Bay Street Toronto ON M5G 0A4 Canada.,Department of Surgery, University of Toronto 149 College Street Toronto ON M5T 1P5 Canada.,Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children Toronto ON M5G 1X8 Canada
| | - Jonathan Irish
- Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada +1-416-581-8473
| | - Robert Weersink
- Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada +1-416-581-8473
| | - Howard J Ginsberg
- Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada +1-416-581-8473.,Department of Surgery, University of Toronto 149 College Street Toronto ON M5T 1P5 Canada.,Keenan Research Center for Biomedical Science, The Li Ka Shing Knowledge Institute, St. Michael's Hospital 30 Bond Street Toronto ON M5B 1W8 Canada
| | - David A Jaffray
- Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada +1-416-581-8473.,Department of Medical Biophysics, University of Toronto 101 College Street Toronto ON M5G 1L7 Canada
| | - Arash Zarrine-Afsar
- Techna Institute for the Advancement of Technology for Health, University Health Network 100 College Street, Room 7-207, MaRS Building, Princess Margaret Cancer Research Tower, 7th floor (STTARR) Toronto ON M5G 1P5 Canada +1-416-581-8473.,Department of Medical Biophysics, University of Toronto 101 College Street Toronto ON M5G 1L7 Canada.,Department of Surgery, University of Toronto 149 College Street Toronto ON M5T 1P5 Canada.,Keenan Research Center for Biomedical Science, The Li Ka Shing Knowledge Institute, St. Michael's Hospital 30 Bond Street Toronto ON M5B 1W8 Canada
| |
Collapse
|
15
|
Zaidi M, Fu F, Cojocari D, McKee TD, Wouters BG. Quantitative Visualization of Hypoxia and Proliferation Gradients Within Histological Tissue Sections. Front Bioeng Biotechnol 2019; 7:397. [PMID: 31867322 PMCID: PMC6906162 DOI: 10.3389/fbioe.2019.00397] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Accepted: 11/22/2019] [Indexed: 12/16/2022] Open
Abstract
The formation of hypoxic microenvironments within solid tumors is known to contribute to radiation resistance, chemotherapy resistance, immune suppression, increased metastasis, and an overall poor prognosis. It is therefore crucial to understand the spatial and molecular mechanisms that contribute to tumor hypoxia formation to improve the efficacy of radiation treatment, develop hypoxia-directed therapies, and increase patient survival. The objective of this study is to present a number of complementary novel methods for quantifying tumor hypoxia and proliferation in multiplexed immunofluorescence images, especially in relation to the location of perfused blood vessels. A standard marker analysis strategy is to take a positive pixel count approach, in which a threshold for positive stain is used to compute a positive area fraction for hypoxia. This work is a reassessment of that approach, utilizing not only cell segmentation but also distance to nearest blood vessel in order to incorporate spatial information into the analysis. We describe a reproducible pipeline for the visualization and quantitative analysis of hypoxia using a vessel distance analysis approach. This methodological pipeline can serve to further elucidate the relationship between vessel distance and microenvironment-linked markers such as hypoxia and proliferation, can help to quantify parameters relating to oxygen consumption and hypoxic tolerance in tissues, as well as potentially serve as a hypothesis generating tool for future studies testing hypoxia-linked markers.
Collapse
Affiliation(s)
- Mark Zaidi
- Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.,STTARR Innovation Centre, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Fred Fu
- STTARR Innovation Centre, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Dan Cojocari
- Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
| | - Trevor D McKee
- STTARR Innovation Centre, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - Bradly G Wouters
- Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.,STTARR Innovation Centre, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| |
Collapse
|
16
|
Hayek G, Luc M, Bloch F, Vermion J, Lhuillier L, Zaidi M, Goetz C, Perone JM. Tobacco smoking in crosslinked keratoconus patients. J Fr Ophtalmol 2019; 42:1001-1006. [DOI: 10.1016/j.jfo.2019.05.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Revised: 04/23/2019] [Accepted: 05/02/2019] [Indexed: 10/26/2022]
|
17
|
Zaidi M, McKee T, Wouters B. Use of Image Analysis to Quantify Hypoxia and Proliferation Relative to Vessel Distance. J Med Imaging Radiat Sci 2019. [DOI: 10.1016/j.jmir.2019.06.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
18
|
Ameloot F, Mezzine H, Khairallah G, Hayek G, Zaidi M, Lhuillier L, Talbi M, Sot M, Perone J. Reconstruction of exenteration socket with Integra® dermal substitute and skin graft. J Fr Ophtalmol 2019; 42:746-752. [DOI: 10.1016/j.jfo.2019.03.023] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Revised: 03/13/2019] [Accepted: 03/20/2019] [Indexed: 11/30/2022]
|
19
|
Perone JM, Goetz C, Zaidi M, Lhuillier L. Supracapsular phacoemulsification: Description of the "Garde à vous" technique and comparative clinical results. J Fr Ophtalmol 2019; 42:597-602. [PMID: 31097313 DOI: 10.1016/j.jfo.2019.03.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2018] [Revised: 02/01/2019] [Accepted: 03/04/2019] [Indexed: 11/17/2022]
Abstract
Phacoemulsification techniques can be divided into 2 categories: endocapsular and supracapsular techniques. Supracapsular techniques involve phacoemulsification of the nucleus outside and above the capsular plane. The "Garde-à-vous" technique described in this manuscript is a modified and improved version of the supracapsular procedure with up-to-date technology in micro-coaxial surgery. It maintains the known advantages of supracapsular techniques such as faster surgical times and lower rates of capsular tears and brings a standardized technique with well-defined surgical steps in order to achieve tilting of the nucleus in a vertical or oblique position in almost 100% of cases by performing a double-wave hydro-dissection. The authors also give the results of a non-randomized prospective study, comparing the "Garde-à-vous" technique and the standard "cracking" technique in 2856 cases. The results show that for the "Garde-à-vous group", the patients were significantly younger (P<0.001), the power of ultrasound used was greater (P<0.001) for lower UST (ultrasound time or average phacoemulsification time APT) and EPT (effective phacoemulsication time) (P<0.001), the duration of the procedure was shorter (P<0.001), patient discomfort was less (P<0.001), and the power of the implants used was lower (P<0.01). With regard to the gender of the patients, the percentage of topical anesthesia and the rate of intraoperative complications (posterior capsular rupture), there was no statistically significant difference.
Collapse
Affiliation(s)
- J-M Perone
- Ophthalmology Department, Metz-Thionville Regional Hospital Center, Mercy Hospital, Metz, France.
| | - C Goetz
- Clinical Research Department, Metz-Thionville Regional Hospital Center, Mercy Hospital, Metz, France
| | - M Zaidi
- Ophthalmology Department, Metz-Thionville Regional Hospital Center, Mercy Hospital, Metz, France
| | - L Lhuillier
- Ophthalmology Department, Metz-Thionville Regional Hospital Center, Mercy Hospital, Metz, France
| |
Collapse
|
20
|
May-Miller P, Zaidi M, Helme S, Mansfield L, Yiangou C, Agrawal A. Can sentinel node biopsy be considered in early breast cancer with axillary nodal disease? Ann Oncol 2019. [DOI: 10.1093/annonc/mdz098.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Zaidi M, Rezacova M, Mansfield L, Helme S, Yiangou C, Agrawal A. Decisions for immediate breast reconstruction: Do surgeons make sensible choices? Ann Oncol 2019. [DOI: 10.1093/annonc/mdz098.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Francois J, Vermion JC, Hayek G, Semler Collery A, Chaussard D, Bloch F, Dubroux C, Lakehal Ayat Y, Lhuillier L, Zaidi M, Perone JM. Management of large central Descemet membrane detachment (DMD) after cataract surgery: Case report and literature review. J Fr Ophtalmol 2019; 42:e271-e278. [PMID: 31029471 DOI: 10.1016/j.jfo.2018.09.024] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Revised: 09/04/2018] [Accepted: 09/12/2018] [Indexed: 11/16/2022]
Affiliation(s)
- J Francois
- Département d'ophtalmologie, hôpital de Mercy, CHR Metz-Thionville, 1, allée du château, CS 45001, 57085 Metz cedex 03, France
| | - J-C Vermion
- Département d'ophtalmologie, hôpital de Mercy, CHR Metz-Thionville, 1, allée du château, CS 45001, 57085 Metz cedex 03, France
| | - G Hayek
- Département d'ophtalmologie, hôpital de Mercy, CHR Metz-Thionville, 1, allée du château, CS 45001, 57085 Metz cedex 03, France
| | - A Semler Collery
- Département d'ophtalmologie, hôpital de Mercy, CHR Metz-Thionville, 1, allée du château, CS 45001, 57085 Metz cedex 03, France
| | - D Chaussard
- Département d'ophtalmologie, hôpital de Mercy, CHR Metz-Thionville, 1, allée du château, CS 45001, 57085 Metz cedex 03, France
| | - F Bloch
- Département d'ophtalmologie, hôpital de Mercy, CHR Metz-Thionville, 1, allée du château, CS 45001, 57085 Metz cedex 03, France
| | - C Dubroux
- Département d'ophtalmologie, hôpital de Mercy, CHR Metz-Thionville, 1, allée du château, CS 45001, 57085 Metz cedex 03, France
| | - Y Lakehal Ayat
- Département d'ophtalmologie, hôpital de Mercy, CHR Metz-Thionville, 1, allée du château, CS 45001, 57085 Metz cedex 03, France
| | - L Lhuillier
- Département d'ophtalmologie, hôpital de Mercy, CHR Metz-Thionville, 1, allée du château, CS 45001, 57085 Metz cedex 03, France
| | - M Zaidi
- Département d'ophtalmologie, hôpital de Mercy, CHR Metz-Thionville, 1, allée du château, CS 45001, 57085 Metz cedex 03, France
| | - J M Perone
- Département d'ophtalmologie, hôpital de Mercy, CHR Metz-Thionville, 1, allée du château, CS 45001, 57085 Metz cedex 03, France.
| |
Collapse
|
23
|
Hassen AB, Rhouma FIH, Daoudi M, Dhahri J, Zaidi M, Abdelmoula N. Influence of defect on the electrical and optical properties of A-site non-stoichiometry Ca0.67La0.22□0.11Ti(1−x)CrxO3−δ perovskite. RSC Adv 2019; 9:19285-19296. [PMID: 35519417 PMCID: PMC9065166 DOI: 10.1039/c9ra02815c] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2019] [Accepted: 05/21/2019] [Indexed: 11/30/2022] Open
Abstract
An investigation of the dielectric dispersion, electrical properties, scaling behavior and optical defects of Ca0.67La0.22□0.11Ti(1−x)CrxO3−δ (CLT(1−x)Crx) with x = 0 and x = 0.1 compositions is presented. The square in the formula is attributed to a vacancy in A-site. Relaxation phenomena were studied with dielectric and modulus formalism, while, the conductivity mechanism was investigated using electrical conductivity. A high permittivity of around 104, low dielectric loss and low electrical conductivity of around 10−3 S cm−1 for Ca0.67La0.22TiO3 (CLT) was observed. These values make this composition interesting for microelectric applications. A comparison between the Z′′ and M′′ indicated that the short-range carrier motion dominates at low temperature and becomes less localized at high temperature. The optical defects of CLT and Ca0.67La0.22Ti0.9Cr0.1O3 (CLT0.9Cr0.1) were studied by electron paramagnetic resonance (EPR) spectroscopy. The results suggest the formation of a [TiO6]9− center, a (Ti3+–VO) center, and dipole defect for CLT compound and Cr3+–VO center defect for CLT0.9Cr0.1 compound. These defects are the source of the in-gap electron traps, which improve the optical properties of CLT(1−x)Crx and hence make it an interesting optical material for different applications. An investigation of the real part of permittivity for the compositions (a) x = 0 and (b) x = 0.1 solid solution Ca0.67La0.22□0.11Ti(1−x)CrxO3−δ ceramics.![]()
Collapse
Affiliation(s)
- A. B. Hassen
- Laboratoire de La Matière Condensée et des Nanosciences
- Département de Physique
- Faculté des Sciences de Monastir
- Tunisia
| | - F. I. H. Rhouma
- Laboratoire de Photovoltaïque de Semi-conducteurs et de Nanostructures
- Centre de Recherche des Scienes et Technologies de L’Energie
- Hammam-Lif 2050
- Tunisia
| | - M. Daoudi
- Laboratoire de Recherche Energie et Matière pour Les Développements des Sciences Nucléaire
- Centre National des Sciences et Technologie Nucléaires
- 2020 Sidi-Thabet
- Tunisia
| | - J. Dhahri
- Laboratoire de La Matière Condensée et des Nanosciences
- Département de Physique
- Faculté des Sciences de Monastir
- Tunisia
| | - M. Zaidi
- Université de Monastir
- Laboratoire de Micro-optoélectroniques et Nanostructures (LMON)
- Monastir 5000
- Tunisia
| | - N. Abdelmoula
- Laboratory of Multifunctional Materials and Applications (LaMMA), (LR16ES18)
- Faculty of Sciences of Sfax
- University of Sfax
- Sfax
- Tunisia
| |
Collapse
|
24
|
Ehrhardt A, Guechi O, Zaidi M, Sot M, Lhuillier L, Houmad N, Ouamara N, Goetz C, Perone JM. Lateral tarsal strip versus lateral tarsal strip with three-snip punctoplasty for managing epiphora in involutional ectropion. J Fr Ophtalmol 2018; 41:752-758. [PMID: 30217604 DOI: 10.1016/j.jfo.2017.12.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2017] [Revised: 12/21/2017] [Accepted: 12/22/2017] [Indexed: 10/28/2022]
Abstract
PURPOSE To compare the efficacy of two surgical techniques-lateral tarsal strip (canthoplasty) alone, and lateral tarsal strip with three-snip punctoplasty-in reducing epiphora arising from involutional ectropion with partial punctal stenosis. METHODS Fourty patients with involutional ectropion and partial stenosis of the lacrimal punctum were randomly allocated to two treatment groups. Group 1 patients received lateral tarsal strip alone with only non-invasive stenting of the punctum, and group 2 patients received tarsal strip plus three-snip punctoplasty. Subjective assessment of epiphora was achieved via completion of a quality of life (QoL) questionnaire preoperatively and at postoperative month 3. Eyelid position, adverse outcomes and corneal dryness (via Oxford grading scheme) were also assessed postoperatively. Only patients with unilateral problems were included in the study. RESULTS Forty eyes of 40 patients were included: 20 in each group. The mean ages of group 1 and group 2 patients were 79±11 and 80±9 years, respectively. All patients reported significantly reduced eye watering after surgery, with no significant intergroup difference in subjective outcomes, except that computer usage and night driving (P<0.05), improved in a more significant way in group 2. Eyelid malposition was corrected in all cases, there were no cases of postoperative punctal eversion, and no significant adverse events or complications occurred. Finally, the mean improvements in the dryness/keratitis score (using the Oxford scheme) were comparable between the 2 groups (P=0.34). CONCLUSION The study findings indicate that treatment of involutional ectropion with partial punctal stenosis by lateral tarsal strip with three snip punctoplasty does not provide greater reduction in discomfort secondary to epiphora than conventional lateral tarsal strip alone, except for specific situations such as night driving or computer use.
Collapse
Affiliation(s)
- A Ehrhardt
- Department of Ophthalmology, CHR Metz-Thionville, Mercy Hospital, 1, allée du Château, 57085 Metz cedex 03, France
| | - O Guechi
- Department of Ophthalmology, CHR Metz-Thionville, Mercy Hospital, 1, allée du Château, 57085 Metz cedex 03, France
| | - M Zaidi
- Department of Ophthalmology, CHR Metz-Thionville, Mercy Hospital, 1, allée du Château, 57085 Metz cedex 03, France
| | - M Sot
- Department of Ophthalmology, CHR Metz-Thionville, Mercy Hospital, 1, allée du Château, 57085 Metz cedex 03, France
| | - L Lhuillier
- Department of Ophthalmology, CHR Metz-Thionville, Mercy Hospital, 1, allée du Château, 57085 Metz cedex 03, France
| | - N Houmad
- Department of Ophthalmology, CHR Metz-Thionville, Mercy Hospital, 1, allée du Château, 57085 Metz cedex 03, France
| | - N Ouamara
- Clinical Research Support Unit, Metz-Thionville Regional Hospital Center, Mercy Hospital, Metz, France
| | - C Goetz
- Department of Ophthalmology, CHR Metz-Thionville, Mercy Hospital, 1, allée du Château, 57085 Metz cedex 03, France; Clinical Research Support Unit, Metz-Thionville Regional Hospital Center, Mercy Hospital, Metz, France
| | - J-M Perone
- Department of Ophthalmology, CHR Metz-Thionville, Mercy Hospital, 1, allée du Château, 57085 Metz cedex 03, France.
| |
Collapse
|
25
|
Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Grénman RA, Caporiccio L, McKee TD, Zaidi M, Butt S, Macann AM, McIvor NP, Chaplin JM, Hicks KO, Bohlander SK, Wouters BG, Hart CP, Print CG, Wilson WR, Curran MA, Hunter FW. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. JCI Insight 2018; 3:122204. [PMID: 30135316 PMCID: PMC6141174 DOI: 10.1172/jci.insight.122204] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2018] [Accepted: 07/13/2018] [Indexed: 01/10/2023] Open
Abstract
Evofosfamide (TH-302) is a clinical-stage hypoxia-activated prodrug of a DNA-crosslinking nitrogen mustard that has potential utility for human papillomavirus (HPV) negative head and neck squamous cell carcinoma (HNSCC), in which tumor hypoxia limits treatment outcome. We report the preclinical efficacy, target engagement, preliminary predictive biomarkers and initial clinical activity of evofosfamide for HPV-negative HNSCC. Evofosfamide was assessed in 22 genomically characterized cell lines and 7 cell line-derived xenograft (CDX), patient-derived xenograft (PDX), orthotopic, and syngeneic tumor models. Biomarker analysis used RNA sequencing, whole-exome sequencing, and whole-genome CRISPR knockout screens. Five advanced/metastatic HNSCC patients received evofosfamide monotherapy (480 mg/m2 qw × 3 each month) in a phase 2 study. Evofosfamide was potent and highly selective for hypoxic HNSCC cells. Proliferative rate was a predominant evofosfamide sensitivity determinant and a proliferation metagene correlated with activity in CDX models. Evofosfamide showed efficacy as monotherapy and with radiotherapy in PDX models, augmented CTLA-4 blockade in syngeneic tumors, and reduced hypoxia in nodes disseminated from an orthotopic model. Of 5 advanced HNSCC patients treated with evofosfamide, 2 showed partial responses while 3 had stable disease. In conclusion, evofosfamide shows promising efficacy in aggressive HPV-negative HNSCC, with predictive biomarkers in development to support further clinical evaluation in this indication.
Collapse
Affiliation(s)
- Stephen Mf Jamieson
- Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand.,Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand.,Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
| | - Peter Tsai
- Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
| | - Maria K Kondratyev
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | - Pratha Budhani
- Department of Immunology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
| | - Arthur Liu
- Department of Immunology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
| | - Neil N Senzer
- Mary Crowley Cancer Research Center, Dallas, Texas, USA
| | - E Gabriela Chiorean
- Indiana University Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, Indiana, USA.,Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, USA
| | - Shadia I Jalal
- Indiana University Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, Indiana, USA
| | - John J Nemunaitis
- Department of Medicine, University of Toledo College of Medicine and Life Sciences, University of Toledo, Toledo, Ohio, USA
| | - Dennis Kee
- LabPLUS, Auckland City Hospital, Auckland, New Zealand
| | - Avik Shome
- Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand
| | - Way W Wong
- Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand
| | - Dan Li
- Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand
| | | | - Purvi M Kakadia
- Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
| | - Nicholas S Knowlton
- Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand.,Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
| | - Courtney Rh Lynch
- Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand
| | - Cho R Hong
- Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand
| | - Tet Woo Lee
- Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand.,Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand
| | - Reidar A Grénman
- Department of Otolaryngology-Head and Neck Surgery, Turku University Hospital, Turku, Finland
| | - Laura Caporiccio
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | - Trevor D McKee
- STTARR Innovation Centre, University Health Network, Toronto, Ontario, Canada
| | - Mark Zaidi
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.,STTARR Innovation Centre, University Health Network, Toronto, Ontario, Canada
| | - Sehrish Butt
- STTARR Innovation Centre, University Health Network, Toronto, Ontario, Canada
| | - Andrew Mj Macann
- Department of Radiation Oncology, Auckland City Hospital, Auckland, New Zealand
| | - Nicholas P McIvor
- Department of Otolaryngology-Head and Neck Surgery, Auckland City Hospital, Auckland, New Zealand
| | - John M Chaplin
- Department of Otolaryngology-Head and Neck Surgery, Auckland City Hospital, Auckland, New Zealand
| | - Kevin O Hicks
- Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand.,Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand
| | - Stefan K Bohlander
- Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand.,Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
| | - Bradly G Wouters
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.,Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.,Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
| | - Charles P Hart
- Threshold Pharmaceuticals, South San Francisco, California, USA
| | - Cristin G Print
- Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand.,Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
| | - William R Wilson
- Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand.,Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand
| | - Michael A Curran
- Department of Immunology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
| | - Francis W Hunter
- Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand.,Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand
| |
Collapse
|
26
|
Zhang J, Liu Q, Cojocari D, Zaidi M, McKee T, Radulovich N, Tsao MS, Hedley D, Koritzinsky M, Wouters BG. Abstract 2443: Oxygen metabolism and hypoxia tolerance in organoid models of pancreatic ductal adenocarcinoma. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-2443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Pancreatic Ductal Adenocarcinoma (PDAC) has extremely heterogeneous hypoxic microenvironments across patients and high levels of hypoxia are correlated with increased tumor aggressiveness and resistance to therapy. However, the underlying genetic contributors to variations in hypoxia and its importance to the disease is currently unknown. We hypothesize that genetic mutations in PDAC associated with two principal factors - oxygen metabolism and hypoxia tolerance - influence the steady state levels of hypoxia in individual tumors. The demand for oxygen, which is influenced by genetic driven changes in cellular metabolism, define the levels and steepness of hypoxia gradients around perfused vessels. Tolerance to hypoxia determines the time tumor cells can survive in severe microenvironments depleted of oxygen and other nutrients. Both factors are affected by the activation of adaptive hypoxia stress response pathways including the HIF, UPR, and autophagy pathways. Method: We developed patient-derived-organoids from PDAC tumors for in vitro studies of oxygen metabolism and glycolytic rates using the Seahorse XF96. We also characterized hypoxia tolerance through monitoring of organoid growth and secondary growth under defined levels of oxygenation. In addition, we have developed an immunofluorescence image analysis pipeline to evaluate in vivo oxygen demand/consumption through the quantification of oxygen and proliferation gradients around perfused blood vessels. Results: We observed significant heterogeneities in oxygen metabolism and hypoxia tolerance across our patient derived organoid models. We also demonstrated the importance of PERK/UPR pathway in mediating both oxygen metabolism and hypoxia tolerance through regulation of ULK1, a kinase involved in the initiation of autophagy. Inhibition or knockdown of ULK1 decreased cell survival and correspondingly sensitized cells to hypoxia in organoid and tumor models. This is accompanied by accumulation of mitochondria and a corresponding increase in oxygen consumption, resulting in increased development of hypoxic cells. Conclusion: These experiments demonstrate the dual importance of oxygen metabolism and hypoxia tolerance and set the stage for the evaluation of these parameters and identification of the underlying genetic drivers of the hypoxic microenvironment. These genetic markers would be used for patient-selection and development of hypoxia-targeted therapies.
Citation Format: Ji Zhang, Qingquan Liu, Dan Cojocari, Mark Zaidi, Trevor McKee, Nikolina Radulovich, Ming-Sound Tsao, David Hedley, Marianne Koritzinsky, Bradly G. Wouters. Oxygen metabolism and hypoxia tolerance in organoid models of pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2443.
Collapse
Affiliation(s)
- Ji Zhang
- 1University of Toronto, Toronto, Ontario, Canada
| | - Qingquan Liu
- 2Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Dan Cojocari
- 1University of Toronto, Toronto, Ontario, Canada
| | - Mark Zaidi
- 2Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Trevor McKee
- 2Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | | | | | - David Hedley
- 2Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | | | | |
Collapse
|
27
|
Wouters B, Cojocari D, Zhang J, McKee T, Zaidi M, Koritzinksy M. SP-0337: Understanding and targeting the underlying drivers of tumor hypoxia. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30647-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
28
|
Dhahri K, Dhahri N, Dhahri J, Taibi K, Hlil EK, Belmabrouk H, Zaidi M. Magnetic, magnetocaloric and critical behavior investigation of La0.7Ca0.1Pb0.2Mn1−x−yAlxSnyO3 (x, y = 0.0, 0.05 and 0.075) prepared by a sol–gel method. RSC Adv 2017. [DOI: 10.1039/c7ra03913a] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A systematic study on the magnetic, magnetocaloric and critical behavior properties of polycrystalline La0.7Ca0.1Pb0.2Mn1−x−yAlxSnyO3 prepared via a sol–gel method are studied.
Collapse
Affiliation(s)
- Khadija Dhahri
- Laboratoire de la matière condensée et des nanosciences
- Département de Physique
- Faculté des Sciences
- Université de Monastir
- Monastir 5019
| | - N. Dhahri
- Laboratoire de la matière condensée et des nanosciences
- Département de Physique
- Faculté des Sciences
- Université de Monastir
- Monastir 5019
| | - J. Dhahri
- Laboratoire de la matière condensée et des nanosciences
- Département de Physique
- Faculté des Sciences
- Université de Monastir
- Monastir 5019
| | | | - E. K. Hlil
- Institut Néel
- CNRS-Université J. Fourier
- Gronoble 38042
- France
| | - Hafedh Belmabrouk
- Department of Physics
- College of Science of Zulfi
- Majmaah University
- Al Majmaah
- Saudi Arabia
| | - M. Zaidi
- Department of Physics
- College of Science of Zulfi
- Majmaah University
- Al Majmaah
- Saudi Arabia
| |
Collapse
|
29
|
Ketfi A, Gharnaout M, Benchia S, Zaidi M, Jaafar M, Ihadadene D. Prise en charge diagnostique et thérapeutique de la tuberculose ganglionnaire. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
30
|
Abstract
The long-held belief that pituitary hormones act solely on master targets was first questioned when we documented G protein-coupled receptors for thyroid-stimulating hormone, follicle-stimulating hormone, adrenocorticotrophic hormone, oxytocin, and vasopressin on bone cells. These evolutionarily conserved hormones and their receptors are known to have primitive roles, and exist in invertebrate species as far down as coelenterates. It is not surprising therefore that each such hormone has multiple hitherto unrecognized functions in mammalian integrative physiology, and hence, becomes a potential target for therapeutic intervention. Here we discuss the skeletal actions of pituitary hormones.
Collapse
Affiliation(s)
- T Yuen
- The Mount Sinai Bone Program, Department of Medicine, and Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - L Sun
- The Mount Sinai Bone Program, Department of Medicine, and Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - P Liu
- The Mount Sinai Bone Program, Department of Medicine, and Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - H C Blair
- Departments of Pathology and of Cell Biology, University of Pittsburgh School of Medicine and the Pittsburgh VA Medical Center, Pittsburgh, PA, United States
| | - M New
- The Mount Sinai Bone Program, Department of Medicine, and Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, United States
| | - A Zallone
- Department of Histology, University of Bari, Bari, Italy
| | - M Zaidi
- The Mount Sinai Bone Program, Department of Medicine, and Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
| |
Collapse
|
31
|
Abstract
TSH and thyroid hormones (T3 and T4) are intimately involved in bone biology. We have previously reported the presence of a murine TSH-β splice variant (TSH-βv) expressed specifically in bone marrow-derived macrophages and that exerted an osteoprotective effect by inducing osteoblastogenesis. To extend this observation and its relevance to human bone biology, we set out to identify and characterize a TSH-β variant in human macrophages. Real-time PCR analyses using human TSH-β-specific primers identified a 364-bp product in macrophages, bone marrow, and peripheral blood mononuclear cells that was sequence verified and was homologous to a human TSH-βv previously reported. We then examined TSH-βv regulation using the THP-1 human monocyte cell line matured into macrophages. After 4 days, 46.1% of the THP-1 cells expressed the macrophage markers CD-14 and macrophage colony-stimulating factor and exhibited typical morphological characteristics of macrophages. Real-time PCR analyses of these cells treated in a dose-dependent manner with T3 showed a 14-fold induction of human TSH-βv mRNA and variant protein. Furthermore, these human TSH-βv-positive cells, induced by T3 exposure, had categorized into both M1 and M2 macrophage phenotypes as evidenced by the expression of macrophage colony-stimulating factor for M1 and CCL-22 for M2. These data indicate that in hyperthyroidism, bone marrow resident macrophages have the potential to exert enhanced osteoprotective effects by oversecreting human TSH-βv, which may exert its local osteoprotective role via osteoblast and osteoclast TSH receptors.
Collapse
Affiliation(s)
- R Baliram
- Thyroid Research Unit (R.B., R.L., S.A.M., T.F.D.) and Mt Sinai Bone Program (R.B., R.L., M.Z., T.F.D.), Icahn School of Medicine at Mt Sinai, Mt Sinai Beth Israel Medical Center, New York, New York 10029; and James J. Peters Veterans Affairs Medical Center, New York, New York 10468
| | - R Latif
- Thyroid Research Unit (R.B., R.L., S.A.M., T.F.D.) and Mt Sinai Bone Program (R.B., R.L., M.Z., T.F.D.), Icahn School of Medicine at Mt Sinai, Mt Sinai Beth Israel Medical Center, New York, New York 10029; and James J. Peters Veterans Affairs Medical Center, New York, New York 10468
| | - S A Morshed
- Thyroid Research Unit (R.B., R.L., S.A.M., T.F.D.) and Mt Sinai Bone Program (R.B., R.L., M.Z., T.F.D.), Icahn School of Medicine at Mt Sinai, Mt Sinai Beth Israel Medical Center, New York, New York 10029; and James J. Peters Veterans Affairs Medical Center, New York, New York 10468
| | - M Zaidi
- Thyroid Research Unit (R.B., R.L., S.A.M., T.F.D.) and Mt Sinai Bone Program (R.B., R.L., M.Z., T.F.D.), Icahn School of Medicine at Mt Sinai, Mt Sinai Beth Israel Medical Center, New York, New York 10029; and James J. Peters Veterans Affairs Medical Center, New York, New York 10468
| | - T F Davies
- Thyroid Research Unit (R.B., R.L., S.A.M., T.F.D.) and Mt Sinai Bone Program (R.B., R.L., M.Z., T.F.D.), Icahn School of Medicine at Mt Sinai, Mt Sinai Beth Israel Medical Center, New York, New York 10029; and James J. Peters Veterans Affairs Medical Center, New York, New York 10468
| |
Collapse
|
32
|
Zaidi M, Bazard M, Dorin J, Machouart M, Angioi K. An unusual germ responsible for fungal keratitis: Metarrhizium Anisopliae. Acta Ophthalmol 2015. [DOI: 10.1111/j.1755-3768.2015.0361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- M. Zaidi
- Meurthe et Moselle; Universitary Hospital of Nancy; Vandoeuvre les Nancy France
| | - M.C. Bazard
- Meurthe et Moselle; Universitary Hospital of Nancy; Vandoeuvre les Nancy France
| | - J. Dorin
- Meurthe et Moselle; Universitary Hospital of Nancy; Vandoeuvre les Nancy France
| | - M. Machouart
- Meurthe et Moselle; Universitary Hospital of Nancy; Vandoeuvre les Nancy France
| | - K. Angioi
- Meurthe et Moselle; Universitary Hospital of Nancy; Vandoeuvre les Nancy France
| |
Collapse
|
33
|
Zubairi I, Zaidi M, Alhasso A, Lumsden G. 1907 CT staging in patients with sentinel or axillary lymph node sampling positive early breast cancer. Is there any impact on clinical outcomes? Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30856-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
34
|
Abstract
We recently demonstrated a direct action of oxytocin (OT) on skeletal homeostasis, mainly mediated through stimulation of osteoblasts (OBs) formation and through the reciprocal modulation of osteoclast (OCs) formation and function. Thus, mice lacking the hormone or its receptor develop a low turnover osteoporosis that worsens with age in both sexes. The skeletons of OT (Ot) and OT receptor (Oxtr) null mice display a pronounced decrease in vertebral and femoral trabecular volume. At the cellular level, OBs from Ot KO and Oxtr KO mice exhibit lower mineralization activity and, at the mRNA level, all master genes for osteoblast differentiation are down-regulated. Moreover, OT has dual effects on OCs: it increases osteoclast formation both directly, by activating nuclear factor kB (NFkB) and mitogen-activated protein kinase (MAPK) signalling and, indirectly, through the up-regulation of receptor activator nuclear factor-kappaB ligand synthesis by OBs. On the other hand, it inhibits bone resorption by triggering cytosolic Ca(2+) release and nitric oxide synthesis in mature OCs. OT is locally produced by osteoblasts acting as paracrine-autocrine regulators of bone formation modulated by oestrogens. The oestrogen signal involved in this feedforward circuit is nongenomic because it requires an intact MAPK kinase signal transduction pathway, instead of the classical nuclear translocation of oestrogen receptor. The ability of oestrogen to increase bone mass in vivo is to some extent OXTR-dependent. Thus, Oxtr KO mice injected 17β-oestradiol did not show any effects on bone formation parameters, whereas the same treatment increases trabecular and cortical bone in wild-type mice. An intact OT autocrine-paracrine circuit appears to be essential for optimal skeletal remodelling.
Collapse
Affiliation(s)
- G Colaianni
- Department of Basic Medical Science, Neuroscience and Sense Organs, Section of Human Anatomy and Histology, University of Bari, Bari, Italy
| | | | | | | | | | | | | |
Collapse
|
35
|
Baliram R, Chow A, Huber AK, Collier L, Ali MR, Morshed SA, Latif R, Teixeira A, Merad M, Liu L, Sun L, Blair HC, Zaidi M, Davies TF. Thyroid and bone: macrophage-derived TSH-β splice variant increases murine osteoblastogenesis. Endocrinology 2013; 154:4919-26. [PMID: 24140716 PMCID: PMC3836071 DOI: 10.1210/en.2012-2234] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
It is now firmly established that TSH may influence the physiology and patho-physiology of bone by activating osteoblasts and inhibiting osteoclast activity resulting in relative osteoprotection. Whether this influence is directly exerted by pituitary-derived TSH in vivo is less certain, because we have previously reported that the suppression of pituitary TSH does not remove such protection. Here, we have characterized the functional relevance of a novel form of the TSH-β subunit, designated TSH-βv, known to be produced by murine bone marrow cells. We found that fresh bone marrow-derived macrophages (MØs) preferentially produced TSH-βv and, when cocultured with CHO cells engineered to overexpress the full-length TSH receptor, were able to generate the production of intracellular cAMP; a phenomenon not seen in control CHO cells, such results confirmed the bioactivity of the TSH variant. Furthermore, cocultures of MØs and osteoblasts were shown to enhance osteoblastogenesis, and this phenomenon was markedly reduced by antibody to TSH-β, suggesting direct interaction between MØs and osteoblasts as observed under the electron microscope. These data suggest a new paradigm of local modulation of bone biology by a MØ-derived TSH-like molecule and raise the question of the relative contribution of local vs pituitary-derived TSH in osteoprotection.
Collapse
Affiliation(s)
- R Baliram
- Room 2F-28, James J. Peters VA Medical Center, 130 West Kingsbridge Road, Bronx, New York, NY 10468.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Zaidi M, Jilani FA, Gupta Y, Umair S, Gupta M. Association between helicobacter pylori and open angle glaucoma: current perspective. Nepal J Ophthalmol 2011; 1:129-35. [PMID: 21141006 DOI: 10.3126/nepjoph.v1i2.3688] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Helicobacter pylori is a Gram negative, spiral-shaped, strictly micro-aerophilic and flagellate human pathogen that can inhabit many areas of stomach. H. pylori infection leads to the generation of oxygen free radicals. H. pylori infection might also aggravate the course of glaucoma by increasing the levels of nitric oxide, endothelin-1 and free radicals indirectly. This article briefly reviews the current perspectives on this issue.
Collapse
Affiliation(s)
- M Zaidi
- Institute of Ophthalmology, Aligarh Muslim University, Aligarh-202002; India.
| | | | | | | | | |
Collapse
|
37
|
Meltzer P, Zaidi M, De Fabo E, Davis S, Hornyak T, Fuchs E, Arnheiter H, Trinchieri G, Noonan F, Merlino G. 28 Ultraviolet B-induced inflammatory microenvironment promotes melanocyte survival and melanoma susceptibility. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70837-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
38
|
De Guglielmo-Cróquer Z, Altosaar I, Zaidi M, Menéndez-Yuffá A. Transformation of coffee (Coffea Arabica L. cv. Catimor) with the cry1ac gene by biolistic, without the use of markers. BRAZ J BIOL 2010; 70:387-93. [DOI: 10.1590/s1519-69842010000200022] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2008] [Accepted: 06/01/2009] [Indexed: 12/24/2022] Open
Abstract
The transformation of coffee plantlets with the cry1ac gene of Bacillus thuringiensis was achieved by biolistic using either the whole pUBC plasmid or only the ubi-cry1ac-nos genetic cassette. The cry1ac gene was inserted into coffee plants in order to confer resistance to the leaf miner Leucoptera coffeella, an insect responsible for considerable losses in coffee crops. Bearing in mind that the genetic cassettes used for this study lack reporter genes and/or selection marker genes, the parameters for the transformation procedure by biolistic were previously standardised with a plasmid carrying the gus reporter gene. The presence of the cry1ac gene in young plantlet tissues was determined by PCR, Southern blot and reverse transcription-PCR. Our results show that the obtainment of viable coffee plantlets, transformed by bombardment with the cry1ac gene and without selection markers nor reporter genes, is feasible.
Collapse
|
39
|
|
40
|
Zaidi M, Azuhairy, Chan CK. Functional Results after Anterior Cruciate Ligament Reconstruction using the bone-patella Tendon-bone Method. Malays Orthop J 2008. [DOI: 10.5704/moj.0804.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
41
|
Zaidi M, Singh N, Kamran M, Ansari N, Nasr SH, Acharya A. Acute onset of hematuria and proteinuria associated with multiorgan involvement of the heart, liver, pancreas, kidneys, and skin in a patient with Henoch-Schönlein purpura. Kidney Int 2007; 73:503-8. [PMID: 18033245 DOI: 10.1038/sj.ki.5002662] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M Zaidi
- Department of Medicine, Bronx VA Medical Center, Mount Sinai School of Medicine, North Central Bronx Hospital, Bronx, New York, USA
| | | | | | | | | | | |
Collapse
|
42
|
Zaidi M. The Second Conference on Skeletal Medicine and Biology: Special Features. Ann N Y Acad Sci 2007; 1117:xiii-xix. [DOI: 10.1196/annals.1402.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
43
|
Zaidi M. The Second Conference on Skeletal Medicine and Biology: Overview and Some Comments. Ann N Y Acad Sci 2007; 1116:xi-xiii. [DOI: 10.1196/annals.1402.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
44
|
|
45
|
Abstract
Calcium transport and calcium signalling mechanisms in bone cells have, in many cases, been discovered by study of diseases with disordered bone metabolism. Calcium matrix deposition is driven primarily by phosphate production, and disorders in bone deposition include abnormalities in membrane phosphate transport such as in chondrocalcinosis, and defects in phosphate-producing enzymes such as in hypophosphatasia. Matrix removal is driven by acidification, which dissolves the mineral. Disorders in calcium removal from bone matrix by osteoclasts cause osteopetrosis. On the other hand, although bone is central to management of extracellular calcium, bone is not a major calcium sensing organ, although calcium sensing proteins are expressed in both osteoblasts and osteoclasts. Intracellular calcium signals are involved in secondary control including cellular motility and survival, but the relationship of these findings to specific diseases is not clear. Intracellular calcium signals may regulate the balance of cell survival versus proliferation or anabolic functional response as part of signalling cascades that integrate the response to primary signals via cell stretch, estrogen, tyrosine kinase, and tumor necrosis factor receptors.
Collapse
Affiliation(s)
- H C Blair
- Department of Pathology, University of Pittsburgh, PA 15261, USA
| | | | | | | |
Collapse
|
46
|
Huang CLH, Sun L, Moonga BS, Zaidi M. Molecular physiology and pharmacology of calcitonin. Cell Mol Biol (Noisy-le-grand) 2006; 52:33-43. [PMID: 17535752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2006] [Revised: 07/10/2006] [Accepted: 05/20/2006] [Indexed: 05/15/2023]
Abstract
Calcitonin is a thirty-two amino acid peptide that contains an N-terminal disulphide bridge and a C-terminal prolineamide residue. It is released from thyroid parafollicular C-cells and its direct actions on the osteoclast account for its physiological effects whether as a hypocalcaemic agent and a potent inhibitor of bone resorption. These effects likely reflect actions upon a number of specific osteoclast cell surface receptors that initiate intracellular signaling events through both cyclic AMP and calcium mediated second messenger pathways. Studies of its potent anti-resorptive effects have significant translational implications in the management of Paget's bone disease, osteoporosis, and hypercalcaemia. This chapter summarizes major concepts in the synthesis and structure of calcitonin and then proceeds to outline its cellular, molecular actions and therapeutic applications, whilst seeking to provide a reference source. More detailed accounts have been given on different aspects of calcitonin physiology and biochemistry in a number of recent reviews by ourselves and others (155,157, Zaidi et al., 1994; 2002).
Collapse
Affiliation(s)
- C L H Huang
- Physiological Laboratory, University of Cambridge, Cambridge, UK.
| | | | | | | |
Collapse
|
47
|
Zorgani AA, Shahen A, Zaidi M, Franka M. A profile and spectrum of four cases of methicillin-resistant Staphylococcus aureus in a burns intensive care unit. Ann Burns Fire Disasters 2006; 19:5-10. [PMID: 21991012 PMCID: PMC3188021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 06/06/2005] [Indexed: 05/31/2023]
Abstract
This report describes and evaluates four patients with hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas infections at the Burns and Plastic Surgery Hospital, in Libya, between August 1999 and August 2002. Neither rifampicin nor vancomycin was used to treat these patients. Inhalation injury with major burns (> 60% total body surface area), a major degree of burns (3rd degree), and septicaemia caused by both MRSA and multi-resistant P. aeruginosa invariably proved fatal. One patient responded well to antibiotic therapy, but the other three died in spite of similar therapy. Vancomycin and rifampicin should be established as the first choice to treat MRSA infection, and infected wounds need aggressive management with antibiotics prior to skin grafting.
Collapse
Affiliation(s)
- A A Zorgani
- Burns and Plastic Surgery Hospital, Tripoli, Libya
| | | | | | | |
Collapse
|
48
|
Epstein S, Zaidi M. Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone 2005; 37:433-40. [PMID: 16046205 DOI: 10.1016/j.bone.2005.05.007] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2005] [Revised: 04/28/2005] [Accepted: 05/20/2005] [Indexed: 12/20/2022]
Abstract
Bisphosphonates, with their proven efficacy and safety, are the most commonly prescribed treatment for women with postmenopausal osteoporosis; however, optimal efficacy is often not achieved due to poor patient adherence to medication. Poor adherence leads to an increased risk of fracture, which itself results in morbidity, elevated healthcare costs and potentially, mortality. Although weekly rather than daily dosing of bisphosphonates has improved adherence, there remains a significant problem, and dosing less frequently than weekly has been suggested as a possible means for further improving adherence. Ibandronate is a new bisphosphonate that has a specific structure and set of characteristics that enable less frequent dosing than currently available bisphosphonates. This review provides details of the general structural features of all bisphosphonates and how these are understood to contribute to their functions in osteoporosis treatment. From this, the unique structure of ibandronate is described, along with how this translates into the high antiresorptive potency, favorable bone-binding, persistence in bone, and good tolerability that permits less frequent dosing. Finally, the clinical evidence for ibandronate is briefly presented, demonstrating the viability of less frequent dosing, with its potential benefits for patient convenience and adherence to therapy.
Collapse
Affiliation(s)
- S Epstein
- Metabolic Bone Unit, Doylestown Hospital, Doylestown, Philadelphia, PA 19073, USA.
| | | |
Collapse
|
49
|
Pazianas M, Butcher GP, Subhani JM, Finch PJ, Ang L, Collins C, Heaney RP, Zaidi M, Maxwell JD. Calcium absorption and bone mineral density in celiacs after long term treatment with gluten-free diet and adequate calcium intake. Osteoporos Int 2005; 16:56-63. [PMID: 15221205 DOI: 10.1007/s00198-004-1641-2] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2003] [Accepted: 03/29/2004] [Indexed: 01/15/2023]
Abstract
Calcium malabsorption, hypocalcemia and skeletal demineralization are well-recognized features of untreated celiac disease. This study investigates calcium absorption and bone mineral density (BMD) after a prolonged, over 4 years, treatment with a gluten-free diet. Twenty-four adult females with treated celiac disease and twenty age- and sex-matched control subjects were studied. Mean body mass index (MBI), energy intake, serum calcium, and serum 25(OH)D concentrations in treated celiacs did not differ from controls. However, while both dietary calcium and protein intake were significantly higher in celiacs (P<0.012), fractional calcium absorption was lower (mean percentage+/-SD; treated 39.8+/-12 versus controls 52.3+/-10, P<0.001). Thus, after adjusting for calcium intake, the estimated amount of calcium absorbed daily was similar in both groups. Whole body, spine and trochanter BMD were significantly lower in treated celiac patients compared with controls (P<0.05). There were significant inverse correlations between: serum parathyroid hormone (PTH) and femoral neck or total body BMD (P<0.01), PTH and duration of gluten-free diet (P=0.05), and fractional calcium absorption and alkaline phosphatase (P=0.022). Increased calcium intake could potentially compensate for the reduced fractional calcium absorption in treated adult celiac patients, but may not normalize the BMD. In addition, the inverse correlation between PTH and time following treatment is suggestive of a continuing long-term benefit of gluten withdrawal on bone metabolism in celiac patients.
Collapse
Affiliation(s)
- M Pazianas
- Department of Medicine, Ralston Penn Center, University of Pennsylvania, 3615 Chestnut Street, Philadelphia, PA 19104, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Khoo KS, Zaidi M, Srimuninnimit V, Jiang ZF, Prem Kumar P, Bustam A, Villalon AH, Lehnert M. Randomized phase II trial of three gemcitabine (GEM)-taxane combinations in metastatic breast cancer (MBC. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.710] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K.-S. Khoo
- National Cancer Centre, Singapore, Singapore; Baquai Institute of Oncology, Karachi, Pakistan; Siriraj Hospital, Mahidol University, Bangkok, Thailand; 307 Hospital, Academy of Military Medical Sciences, Beijing, China; MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, India; University Malaya Medical Centre, Kuala Lumpar, Malaysia; Manila Doctors Hospital, Manila, Philippines; Eli Lilly Asian Operations Ltd, Hong Kong, China
| | - M. Zaidi
- National Cancer Centre, Singapore, Singapore; Baquai Institute of Oncology, Karachi, Pakistan; Siriraj Hospital, Mahidol University, Bangkok, Thailand; 307 Hospital, Academy of Military Medical Sciences, Beijing, China; MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, India; University Malaya Medical Centre, Kuala Lumpar, Malaysia; Manila Doctors Hospital, Manila, Philippines; Eli Lilly Asian Operations Ltd, Hong Kong, China
| | - V. Srimuninnimit
- National Cancer Centre, Singapore, Singapore; Baquai Institute of Oncology, Karachi, Pakistan; Siriraj Hospital, Mahidol University, Bangkok, Thailand; 307 Hospital, Academy of Military Medical Sciences, Beijing, China; MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, India; University Malaya Medical Centre, Kuala Lumpar, Malaysia; Manila Doctors Hospital, Manila, Philippines; Eli Lilly Asian Operations Ltd, Hong Kong, China
| | - Z. F. Jiang
- National Cancer Centre, Singapore, Singapore; Baquai Institute of Oncology, Karachi, Pakistan; Siriraj Hospital, Mahidol University, Bangkok, Thailand; 307 Hospital, Academy of Military Medical Sciences, Beijing, China; MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, India; University Malaya Medical Centre, Kuala Lumpar, Malaysia; Manila Doctors Hospital, Manila, Philippines; Eli Lilly Asian Operations Ltd, Hong Kong, China
| | - P. Prem Kumar
- National Cancer Centre, Singapore, Singapore; Baquai Institute of Oncology, Karachi, Pakistan; Siriraj Hospital, Mahidol University, Bangkok, Thailand; 307 Hospital, Academy of Military Medical Sciences, Beijing, China; MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, India; University Malaya Medical Centre, Kuala Lumpar, Malaysia; Manila Doctors Hospital, Manila, Philippines; Eli Lilly Asian Operations Ltd, Hong Kong, China
| | - A. Bustam
- National Cancer Centre, Singapore, Singapore; Baquai Institute of Oncology, Karachi, Pakistan; Siriraj Hospital, Mahidol University, Bangkok, Thailand; 307 Hospital, Academy of Military Medical Sciences, Beijing, China; MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, India; University Malaya Medical Centre, Kuala Lumpar, Malaysia; Manila Doctors Hospital, Manila, Philippines; Eli Lilly Asian Operations Ltd, Hong Kong, China
| | - A. H. Villalon
- National Cancer Centre, Singapore, Singapore; Baquai Institute of Oncology, Karachi, Pakistan; Siriraj Hospital, Mahidol University, Bangkok, Thailand; 307 Hospital, Academy of Military Medical Sciences, Beijing, China; MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, India; University Malaya Medical Centre, Kuala Lumpar, Malaysia; Manila Doctors Hospital, Manila, Philippines; Eli Lilly Asian Operations Ltd, Hong Kong, China
| | - M. Lehnert
- National Cancer Centre, Singapore, Singapore; Baquai Institute of Oncology, Karachi, Pakistan; Siriraj Hospital, Mahidol University, Bangkok, Thailand; 307 Hospital, Academy of Military Medical Sciences, Beijing, China; MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, India; University Malaya Medical Centre, Kuala Lumpar, Malaysia; Manila Doctors Hospital, Manila, Philippines; Eli Lilly Asian Operations Ltd, Hong Kong, China
| |
Collapse
|